argenex SE (NASDAQ:ARGX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on argenex, with 17 buy ratings, two strong-buy ratings and five holds among 24 firms. The average 12-month price target is $1,158.61.
• argenex reported quarterly EPS of $7.32, exceeding the $5.86 consensus estimate, while revenue of $1.54 billion also topped expectations of $1.45 billion.
• ARGX shares opened at $919.21, down 1.8%, with a market capitalization of approximately $57.51 billion; institutional investors own 60.32% of the company.

argenex SE (NASDAQ:ARGX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-four research firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $1,158.61.

Several research analysts have recently commented on ARGX shares. Deutsche Bank Aktiengesellschaft downgraded argenex from a "buy" rating to a "hold" rating in a report on Monday, August 24th. Wall Street Zen cut argenex from a "buy" rating to a "hold" rating in a report on Saturday, September 19th. Piper Sandler lifted their price objective on argenex from $1,075.00 to $1,215.00 and gave the company an "overweight" rating in a research report on Monday, August 17th. Guggenheim initiated coverage on argenex in a research note on Tuesday, August 4th. They issued a "buy" rating and a $1,185.00 price objective on the stock. Finally, Oppenheimer boosted their price objective on argenex from $1,014.00 to $1,037.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th.

argenex Stock Down 1.8%

Shares of argenex stock opened at $919.21 on Friday. argenex has a 12-month low of $661.85 and a 12-month high of $1,072.75. The stock has a market capitalization of $57.51 billion, a P/E ratio of 35.30, a price-to-earnings-growth ratio of 0.95 and a beta of 0.44. The company has a 50-day simple moving average of $959.02 and a 200 day simple moving average of $869.32.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating analysts' consensus estimates of $5.86 by $1.46. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. On average, equities analysts anticipate that argenex will post 29.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its position in argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company's stock valued at $1,847,592,000 after buying an additional 83,568 shares during the last quarter. Sands Capital Management LLC raised its position in shares of argenex by 2,046.6% during the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company's stock worth $300,110,000 after acquiring an additional 340,245 shares during the last quarter. Fiera Capital Corp lifted its stake in shares of argenex by 27.2% during the fourth quarter. Fiera Capital Corp now owns 225,971 shares of the company's stock valued at $190,030,000 after acquiring an additional 48,317 shares during the period. Jennison Associates LLC lifted its stake in shares of argenex by 3.4% during the first quarter. Jennison Associates LLC now owns 237,468 shares of the company's stock valued at $173,411,000 after acquiring an additional 7,707 shares during the period. Finally, Lord Abbett & CO. LLC boosted its holdings in argenex by 3.5% in the fourth quarter. Lord Abbett & CO. LLC now owns 203,864 shares of the company's stock valued at $171,439,000 after acquiring an additional 6,987 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

About argenex

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx's leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.